HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer

Sponsor
National Cancer Institute, Naples
Study ID
NCT00401427
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The combination of vinorelbine with weekly trastuzumab has produced high response rate in HER2 overexpressing metastatic breast cancer (MBC). The present phase 2 study was planned to test activity of the same combination, with trastuzumab given every 3 weeks, rather than weekly.

Key Dates

Start date
Nov 30, 2002
Status verified
Jul 2012
Primary completion
Jun 30, 2006
Completion
Dec 31, 2006

Study Design

Enrollment
50 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

response rate

Related Studies